Privia Health Group, Inc. (PRVA)
NEUTRALファンダメンタル
62
株価
$20.90
時価総額
$2.70B
パート1 · 企業の価値
概要
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. The company was founded in 2007 and is headquartered in Arlington, Virginia.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$2.36B
直近12か月(2026/6/30まで)
純利益
$28M
直近12か月(2026/6/30まで)
フリーキャッシュフロー
-
自己資本合計
$737M
負債合計
$578M
流動比率
1.62
利払い倍率
-
負債/EBITDA
0.20
一株当たり利益(EPS)
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$19.19
現在株価
$20.90
安全マージン
-8.9%
適正価値レンジ
$12.47 - $25.90
推定方法
バリュエーション指標
P/E レシオ
95.55
ROE
3.1%
P/B レシオ
3.43
P/FCF
-
粗利益率
-
ROIC
4.2%
収益性レーダー
Value Creation (Economic Moat)
ROIC
4.2%
WACC
8.9%
ROIC − WACC
-4.8 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
ファンダメンタル分析基準
合格(13)
- EPS shows upward trend
- EPS CAGR 12.25%
- Debt/Equity ratio
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 21.0%
- Analyst Consensus 88% Buy
- Earnings Surprise avg 3.9%
- Earnings Quality (OCF/NI) 4.66
- Share Dilution -2.6%
- Net Margin Trend 1.2% vs 0.8%
- Piotroski F-Score 6/9
不合格(8)
- Price CAGR -3.98%
- ROIC 4.2%
- P/B Ratio 3.43
- Operating Margin 1.9%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.8%
データなし(7)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
まちまちのシグナル:一部の領域に注意が必要
利益の質
高品質:利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Parth Mehrotra | CEO & Director | 46 |
| Mr. David Mountcastle CPA, MBA | Executive VP & CFO | 55 |
| Mr. Edward Christopher Fargis Esq. | Executive VP, General Counsel, Chief Legal Officer & Corporate Secretary | 60 |
| Mr. Sarath Degala | Chief Operating Officer | - |
| Mr. Konda Mullapudi | Executive VP & CTO | - |
| Mr. Robert P. Borchert | Senior Vice President of Investor Relations & Corporate Communications | - |
| Ms. Dana Fields CPA | Chief Audit & Compliance Officer | - |
| Ms. Jenny Harding | Chief People Officer | - |
| Mr. Jay Stevens | Senior VP & Chief Growth Officer | - |
| Mr. Eric J. Beyer | Executive Vice President of Medical Groups | - |
監査リスク
1
取締役会リスク
2
報酬リスク
3
株主権利リスク
6
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for PRVA, sourced from Markets Gazette.
- 2/26/2026NEUTRALPrivia Health (PRVA) Q4 2025 Earnings Transcript
The financial market is currently awaiting the detailed transcript of Privia Health's (PRVA) Q4 2025 earnings call. While the specific content remains unavailable, investors will be keenly scrutinizing this document for clarity on the company's financial health and future trajectory. Earnings transcripts are vital as they provide direct insights from management discussions, detailing revenues, profits, operating margins, and crucially, future guidance. The current lack of concrete data keeps the stock in a state of anticipation, with market participants looking for signals regarding patient growth, geographical expansion, and cost management strategies. The stock's reaction will heavily depend on the tone and figures revealed once the full transcript is released.
via Markets Gazette